Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis-Reference-Cited by-同舟云学术

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis

Published:2017-07-05 Issue:10 Volume:6 Page:e1345402
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Romano Marco¹²,Sollazzo Daria¹,Trabanelli Sara³,Barone Martina¹,Polverelli Nicola¹,Perricone Margherita¹,Forte Dorian¹,Luatti Simona¹,Cavo Michele¹,Vianelli Nicola¹,Jandus Camilla³,Palandri Francesca¹,Catani Lucia¹

Affiliation:

1. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli,” University of Bologna, Bologna, Italy

2. Immunoregulation Laboratory, Division of Transplantation Immunology & Mucosal Biology, MRC Centre for Transplantation, King's College London, Guy's Hospital, UK

3. Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1345402

Reference44 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

2. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects

3. Calreticulin Mutations in Myeloproliferative Neoplasms

4. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

5. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape;International Journal of Molecular Sciences;2023-12-12

2. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis;Future Oncology;2023-11-22

3. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow;Frontiers in Immunology;2023-08-17

4. Soluble Collectin 11 (CL-11) Acts as an Immunosuppressive Molecule Potentially Used by Stem Cell-Derived Retinal Epithelial Cells to Modulate T Cell Response;Cells;2023-07-07

5. Arginase‐1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver;Cancer Medicine;2022-12-15